Fast Locator 2011-2012: Cangene bioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Cangene bioPharma



CANGENE bioPharma, is a contract manufacturer, providing fill/finish and support services for over 30 years. Located in Baltimore, MD, USA, close to the FDA, CANGENE bioPharma is highly compliant, having successfully passed inspections from numerous regulatory agencies in the US, EU, and Japan.

CANGENE bioPharma’s fill/finish services include:

  • Vial filling (3cc-100cc) - batches up to 85,000 5cc vials
  • Lyophilization (2 x 240 sq ft lyophilizers)
  • Syringe filling – 0.5cc–20cc syringes
  • Terminal Sterilization – with steam

CANGENE bioPharma prides itself on providing outstanding and flexible support to its partner companies. From clinical through commercial launch, CANGENE bioPharma has the experience, knowledgeable personnel and involved management team to ensure our partners’ products proceed from project initiation through manufacturing quickly with an emphasis on exceptional quality.

CANGENE bioPharma provides services to a worldwide customer base, including large, small and virtual pharmaceutical and biotechnology companies. CANGENE bioPharma produces products that are distributed in over 50 countries by our clients.


Regions covered:

North America


Outsourcing services provided:

Development and Phase I/II CTM

  • Injectable products development

Commercial Manufacturing

  • Injectables

Analytical Services

  • Chemistry and stability
  • Microbiology

Website:

www.cangenebiopharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search

Click here